Hospital
Page Memorial Hospital, INC.
Page Memorial Hospital, INC. was paid $14.04M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoPAGE MEMORIAL HOSPITAL, INC.
LURAY, VA 22835
LURAY, VA 22835
33aNPI1326040684assigned 06/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.04M
24GClaims189,096
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#43 of 80
Median peer was paid$14.69M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JOHNSON, RENEE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,735 | $458K | |
| 2019 | 24,771 | $1.21M | |
| 2020 | 22,713 | $1.58M | |
| 2021 | 28,781 | $2.00M | |
| 2022 | 33,292 | $2.58M | |
| 2023 | 36,817 | $3.12M | |
| 2024incomplete | 30,987 | $3.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 25,093 | 22,514 | $4.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 8,922 | 7,788 | $1.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 13,201 | 12,066 | $1.82M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.5% | 3,009 | 2,654 | $1.33M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.0% | 6,497 | 1,833 | $695K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 2,339 | 2,186 | $534K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,186 | 1,122 | $480K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 1,420 | 1,336 | $436K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.0% | 4,072 | 3,864 | $415K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 1,326 | 981 | $302K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 3,539 | 3,151 | $242K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 9,493 | 8,928 | $181K |
102 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 391 | $155K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 8,975 | $154K |
| 97161 | 1.1% | 748 | $152K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 419 | $109K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,284 | $80K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,828 | $75K |
| 80053 | Comprehensive metabolic panel | <1% | 11,457 | $75K |
| 87428 | <1% | 2,653 | $74K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 170 | $51K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 626 | $48K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,445 | $34K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 334 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,944 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,866 | $26K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,599 | $25K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,534 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,556 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,740 | $19K |
| 96376 | <1% | 263 | $18K | |
| 81025 | <1% | 1,793 | $17K | |
| 73564 | <1% | 440 | $17K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,205 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,402 | $14K |
| 73630 | <1% | 429 | $14K | |
| 83880 | <1% | 672 | $13K | |
| 80061 | Lipid panel | <1% | 1,312 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,806 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,128 | $11K |
| 73610 | <1% | 238 | $11K | |
| 73030 | <1% | 169 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 479 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,312 | $9K |
| 85379 | <1% | 790 | $8K | |
| 81002 | <1% | 2,413 | $8K | |
| 81003 | <1% | 2,743 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 97 | $7K |
| 85610 | <1% | 2,360 | $6K | |
| 81001 | <1% | 3,865 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 30 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,170 | $5K |
| 87634 | <1% | 230 | $4K | |
| 87420 | <1% | 172 | $4K | |
| 84484 | <1% | 2,553 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $4K |
| 87807 | <1% | 394 | $3K | |
| 80143 | <1% | 524 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 230 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 416 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 51 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 27 | $2K |
| 73110 | <1% | 62 | $2K | |
| 80306 | <1% | 1,540 | $2K | |
| 80179 | <1% | 459 | $1K | |
| 73130 | <1% | 67 | $1K | |
| 87081 | <1% | 1,932 | $1K | |
| 83735 | <1% | 771 | $1K | |
| 83690 | <1% | 1,605 | $922.27 | |
| 86140 | <1% | 151 | $847.79 | |
| 82607 | <1% | 83 | $827.59 | |
| 84703 | <1% | 885 | $791.58 | |
| 73080 | <1% | 16 | $643.28 | |
| 84439 | <1% | 70 | $633.88 | |
| 82746 | <1% | 63 | $606.92 | |
| 94664 | <1% | 166 | $599.37 | |
| 93000 | <1% | 43 | $524.82 | |
| 84466 | <1% | 58 | $504.47 | |
| 82728 | <1% | 30 | $390.42 | |
| 86803 | <1% | 24 | $340.82 | |
| 85730 | <1% | 1,090 | $336.97 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,313 | $295.23 |
| 82947 | <1% | 22 | $294.49 | |
| 85652 | <1% | 98 | $294.25 | |
| 87186 | <1% | 441 | $292.06 | |
| 80050 | General health panel | <1% | 15 | $282.30 |
| 83540 | <1% | 58 | $277.36 | |
| 87040 | <1% | 60 | $242.82 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 750 | $204.14 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 173 | $133.07 |
| 83605 | <1% | 141 | $120.27 | |
| 85027 | <1% | 95 | $89.16 | |
| 86769 | <1% | 19 | $77.85 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $66.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,124 | $61.74 |
| 87077 | <1% | 107 | $50.33 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,246 | $46.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 75 | $27.70 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 229 | $27.65 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 361 | $27.22 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 267 | $23.88 |
| J3490 | Unclassified drugs | <1% | 305 | $23.39 |
| 82948 | <1% | 57 | $12.19 | |
| 82550 | <1% | 15 | $7.93 | |
| 80076 | <1% | 15 | $6.85 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 81 | $6.68 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 93 | $5.96 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 58 | $0.00 |
| 94760 | 0% | 43 | $0.00 | |
| 87088 | 0% | 12 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 189 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 17 | $0.00 |
| 80047 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, RENEE (CREDENTIALING COORDINATOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.